for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Esperion To Present Data From Late-Stage and Mid-Stage Trials Testing NEXLETOL™ And NEXLIZET™

March 23 (Reuters) - Esperion Therapeutics Inc:

* ESPERION ANNOUNCES POOLED ANALYSES FROM PHASE 3 LDL-C LOWERING DEVELOPMENT PROGRAM OF THE NEXLETOL™ (BEMPEDOIC ACID) TABLET AND PHASE 2 STUDY RESULTS OF THE NEXLIZET™ (BEMPEDOIC ACID AND EZETIMIBE) TABLET TO BE PRESENTED AT THE AMERICAN COLLEGE OF CARDIOLOGY’S 69TH ANNUAL SCIENTIFIC SESSION TOGETHER WITH WORLD CONGRESS OF CARDIOLOGY (ACC.20/WCC) Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up